Mycoplasma in Poultry: Causes, Clinical Signs in Chicken Poop, and Control Strategies
By Dr. Zubair Khalid, DVM, MS, PhD ·
Key Takeaways
- Avian mycoplasmosis, primarily caused by Mycoplasma gallisepticum (MG) and Mycoplasma synoviae (MS), is a significant economic threat to poultry, leading to chronic respiratory disease, synovitis, and reduced egg production.
- Clinical signs can include respiratory distress (rales, coughing), lameness, joint swelling, and notably, greenish or yellowish-green diarrhea due to biliverdin excretion, often indicative of anorexia and systemic inflammation.
- Diagnosis relies on a combination of serological tests (ELISA, RSA) for flock screening and highly sensitive molecular methods like PCR and qPCR for specific pathogen detection and strain differentiation.
- Control strategies are multifaceted, emphasizing stringent biosecurity, strategic vaccination with live-attenuated or inactivated vaccines, and judicious antimicrobial therapy, though antimicrobial resistance is a growing concern.
- Emerging diagnostic technologies include isothermal amplification (LAMP, RAA) and CRISPR-based systems for rapid, field-deployable detection, while alternative control approaches like phytogenic compounds are under investigation.
1. Introduction
Avian mycoplasmosis represents a group of economically significant infectious diseases affecting poultry worldwide, primarily caused by pathogenic species within the genus Mycoplasma [<a href="#ref-1">1</a>]. The most clinically relevant species in commercial poultry are Mycoplasma gallisepticum (MG) and Mycoplasma synoviae (MS), though other species such as Mycoplasma meleagridis and Mycoplasma iowae also cause disease in turkeys [<a href="#ref-2">2</a>, <a href="#ref-3">3</a>]. These organisms are classified within the class Mollicutes, characterized by the absence of a cell wall, a reduced genome size, and a dependence on host-derived nutrients for survival [<a href="#ref-1">1</a>]. The lack of a cell wall renders these bacteria intrinsically resistant to beta-lactam antimicrobials and confers a unique set of vulnerabilities and diagnostic challenges [<a href="#ref-4">4</a>, <a href="#ref-5">5</a>]. Infections with MG and MS lead to chronic respiratory disease, synovitis, airsacculitis, and egg production losses, resulting in substantial economic burdens for the poultry industry [<a href="#ref-3">3</a>, <a href="#ref-6">6</a>]. This article provides a detailed examination of the causes of avian mycoplasmosis, the clinical manifestations with a specific focus on fecal abnormalities, and a comprehensive overview of current and emerging control strategies.
2. Etiology and Pathogen Biology
2.1. The Genus Mycoplasma
Mycoplasmas are the smallest self-replicating organisms, with genomes ranging from approximately 0.58 to 1.38 Mb [<a href="#ref-1">1</a>]. Their minimalistic genome encodes a reduced metabolic repertoire, necessitating a parasitic or saprophytic lifestyle [<a href="#ref-1">1</a>]. The cell membrane is composed of a lipid bilayer with embedded proteins, including variable surface lipoproteins that play critical roles in antigenic variation and immune evasion [<a href="#ref-6">6</a>]. Comparative genomic analyses have revealed that avian mycoplasmas possess a core set of genes essential for host colonization and basic metabolism, along with species-specific genes associated with virulence and host tropism [<a href="#ref-1">1</a>].
2.2. Primary Pathogenic Species
Mycoplasma gallisepticum is the primary etiological agent of chronic respiratory disease (CRD) in chickens and infectious sinusitis in turkeys [<a href="#ref-2">2</a>, <a href="#ref-3">3</a>]. MG is a highly contagious pathogen that colonizes the respiratory epithelium, leading to inflammation, ciliostasis, and secondary bacterial infections [<a href="#ref-6">6</a>]. Mycoplasma synoviae is the causative agent of infectious synovitis, characterized by inflammation of the synovial membranes of joints and tendon sheaths, and can also cause respiratory disease and eggshell apex abnormalities (EAA) [<a href="#ref-7">7</a>, <a href="#ref-8">8</a>, <a href="#ref-9">9</a>]. Both MG and MS can be transmitted horizontally through direct contact, airborne droplets, and contaminated fomites, as well as vertically through the egg [<a href="#ref-10">10</a>, <a href="#ref-11">11</a>]. Mycoplasma meleagridis primarily affects turkeys, causing airsacculitis and leg deformities, while Mycoplasma iowae is associated with reduced hatchability and embryo mortality [<a href="#ref-3">3</a>, <a href="#ref-12">12</a>].
2.3. Pathogenesis and Host Interaction
The pathogenic mechanisms of avian mycoplasmas involve adherence to host epithelial cells, evasion of the host immune response through antigenic variation, and the induction of pro-inflammatory cytokines [<a href="#ref-6">6</a>, <a href="#ref-13">13</a>]. MG uses adhesins such as GapA and CrmA to bind to tracheal epithelial cells, leading to ciliary stasis and loss of mucociliary clearance [<a href="#ref-6">6</a>]. The organism also activates the MAPK pathway and induces autophagy in host cells, contributing to tissue damage and inflammation [<a href="#ref-13">13</a>, <a href="#ref-14">14</a>]. MS employs glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a moonlighting protein to facilitate colonization of the lower respiratory tract [<a href="#ref-15">15</a>, <a href="#ref-16">16</a>]. The organism also triggers inflammatory and apoptotic responses in avian macrophages via the PIK3CA pathway [<a href="#ref-17">17</a>]. Co-infections with other pathogens, such as Pasteurella multocida, Avibacterium paragallinarum, or Cryptosporidium baileyi, can exacerbate disease severity [<a href="#ref-2">2</a>, <a href="#ref-7">7</a>, <a href="#ref-18">18</a>].
3. Clinical Signs and Fecal Abnormalities
3.1. Respiratory and Systemic Signs
Clinical signs of MG infection in chickens include rales, coughing, sneezing, nasal discharge, and conjunctivitis [<a href="#ref-3">3</a>, <a href="#ref-6">6</a>]. In turkeys, MG causes swelling of the infraorbital sinuses. MS infection presents with lameness, swollen joints (hock and wing joints), and sternal bursitis [<a href="#ref-8">8</a>, <a href="#ref-19">19</a>]. Systemic signs include decreased feed intake, reduced growth rates, and a drop in egg production [<a href="#ref-10">10</a>, <a href="#ref-20">20</a>]. Chronic infections may result in airsacculitis, which leads to increased condemnation rates at slaughter [<a href="#ref-18">18</a>, <a href="#ref-21">21</a>].
3.2. Fecal Abnormalities in Mycoplasma-Infected Poultry
While respiratory and joint signs are the predominant clinical features of avian mycoplasmosis, gastrointestinal manifestations are also observed, particularly in cases of severe systemic infection or co-infection with enteric pathogens. The classic clinical sign associated with MG and MS infection in chicken droppings is the presence of greenish or yellowish-green diarrhea. This fecal discoloration results from the excretion of biliverdin, a green bile pigment, secondary to anorexia and cholestasis induced by systemic inflammation [<a href="#ref-9">9</a>]. As infected birds reduce feed intake due to malaise, respiratory distress, or lameness, bile pigment metabolism is altered, leading to green-tinged feces.
In cases of MS-induced synovitis, the pain and reluctance to move can lead to dehydration and reduced water consumption, resulting in the production of pasty, urate-rich droppings with a chalky white appearance due to increased uric acid concentration. The diarrhea associated with mycoplasmosis is typically not hemorrhagic; the presence of frank blood in the feces is more indicative of coccidiosis (e.g., Eimeria tenella, E. necatrix) or necrotic enteritis (Clostridium perfringens), which may occur as co-infections [<a href="#ref-2">2</a>, <a href="#ref-3">3</a>].
Loose, watery droppings (diarrhea) can occur due to enteric involvement or as a non-specific sign of fever and systemic illness. However, primary mycoplasma-induced enteritis is uncommon; gastrointestinal signs are typically secondary to systemic disease or co-infection with other pathogens. For example, co-infection with Cryptosporidium baileyi has been shown to enhance MS colonization in chickens, potentially aggravating intestinal pathology and leading to malabsorptive diarrhea [<a href="#ref-7">7</a>]. The stress induced by chronic mycoplasma infection can disrupt the gut microbiome, leading to dysbiosis and loose droppings [<a href="#ref-22">22</a>].
3.3. Differential Diagnosis of Fecal Abnormalities
The clinical sign of green diarrhea in poultry warrants a broad differential diagnosis, including highly pathogenic avian influenza (HPAI), Newcastle disease, fowl cholera, and salmonellosis. The presence of joint swelling and respiratory signs, along with a history of slow spread within a flock, helps differentiate mycoplasmosis from acute viral infections. Metabolomics studies have identified potential biomarkers, including altered bile acid profiles, in the plasma of MS-infected hens that correlate with systemic metabolic derangements [<a href="#ref-9">9</a>, <a href="#ref-23">23</a>].
Table 1: Differential Diagnosis of Fecal Abnormalities in Poultry
| Condition | Fecal Appearance | Key Associated Signs | Primary Etiology |
|---|---|---|---|
| Mycoplasmosis | Greenish diarrhea; pasty urate droppings | Respiratory rales, lameness, sinus swelling | M. gallisepticum, M. synoviae |
| Avian Influenza (HPAI) | Watery green diarrhea, blood-tinged | Sudden death, cyanosis, edema | Influenza A virus |
| Newcastle Disease | Greenish watery diarrhea | Respiratory distress, nervous signs, egg drop | Avian paramyxovirus 1 |
| Coccidiosis | Bloody or mucoid feces | Weight loss, anemia, cecal lesions | Eimeria spp. |
| Necrotic Enteritis | Dark, tarry or loose brown feces | Sudden death, liver necrosis | Clostridium perfringens |
| Salmonellosis | White, pasty diarrhea (pullorum) | Weakness, huddling, depression | Salmonella spp. |
4. Diagnostic Approaches
4.1. Traditional Diagnostic Methods
A definitive diagnosis of avian mycoplasmosis relies on isolation of the organism in specialized media [<a href="#ref-24">24</a>]. However, mycoplasmas are fastidious, slow-growing organisms that require extended incubation periods, making culture impractical for rapid diagnosis [<a href="#ref-4">4</a>, <a href="#ref-24">24</a>]. Serological tests, including the rapid serum agglutination (RSA) test and enzyme-linked immunosorbent assay (ELISA), are widely used for flock-level screening [<a href="#ref-25">25</a>, <a href="#ref-26">26</a>]. Commercial ELISA kits designed to detect antibodies against MG and MS are available, although cross-reactivity between species and variability in antibody responses necessitate confirmatory testing [<a href="#ref-26">26</a>, <a href="#ref-27">27</a>].
4.2. Molecular Diagnostics
Polymerase chain reaction (PCR)-based methods have become the gold standard for the rapid and specific detection of avian mycoplasmas [<a href="#ref-28">28</a>, <a href="#ref-29">29</a>, <a href="#ref-30">30</a>]. Conventional, multiplex, and real-time quantitative PCR (qPCR) assays targeting species-specific genes, such as the mgc2 gene for MG and the vlhA gene for MS, offer high sensitivity and specificity [<a href="#ref-28">28</a>, <a href="#ref-30">30</a>, <a href="#ref-31">31</a>]. A duplex qPCR assay for MG can distinguish between wild-type and vaccine strains (e.g., ts-11), enabling effective surveillance of vaccination programs [<a href="#ref-28">28</a>, <a href="#ref-29">29</a>].
Droplet digital PCR (ddPCR) provides absolute quantification of target DNA without the need for standard curves, and has been developed for detecting MG in duck flocks [<a href="#ref-32">32</a>]. TaqMan-MGB probe-based real-time PCR assays have been designed to differentiate the MS-H vaccine strain from wild-type MS strains by targeting specific single nucleotide polymorphisms (SNPs) [<a href="#ref-33">33</a>, <a href="#ref-34">34</a>, <a href="#ref-35">35</a>].
4.3. Advanced and Point-of-Care Technologies
Isothermal amplification methods, such as loop-mediated isothermal amplification (LAMP) and recombinase-aided amplification (RAA), enable field-deployable and point-of-care detection [<a href="#ref-36">36</a>, <a href="#ref-37">37</a>, <a href="#ref-38">38</a>]. Colorimetric LAMP assays coupled with rapid DNA extraction methods allow for visual detection of MG without specialized equipment, making them suitable for resource-limited settings [<a href="#ref-36">36</a>, <a href="#ref-37">37</a>]. The combination of RAA with CRISPR/Cas12a systems provides highly specific and sensitive detection platforms for both MG and MS [<a href="#ref-38">38</a>, <a href="#ref-39">39</a>]. A gold nanoparticle-based lateral flow immunoassay has been developed for the simultaneous detection of three avian mycoplasmas, offering a user-friendly, rapid screening tool [<a href="#ref-40">40</a>].
High-throughput sequencing and genomic analysis provide valuable insights into pathogen diversity, antimicrobial resistance determinants, and evolutionary dynamics [<a href="#ref-12">12</a>, <a href="#ref-41">41</a>, <a href="#ref-42">42</a>, <a href="#ref-43">43</a>].
Figure 1: Diagnostic Workflow for Avian Mycoplasmosis
graph TD
A["Clinical Signs: Respiratory, Joint, Fecal"] --> B{"Flock-Level Screening"}
B --> C["Serology: RSA, ELISA"]
C --> D{"Positive Result?"}
D -- Yes --> E["Molecular Confirmation"]
D -- No --> F["Rule Out Other Pathogens"]
E --> G["DNA Extraction from Swabs/Tissues"]
G --> H["Species-Specific PCR/qPCR"]
H --> I{"Specific Detection"}
I -- MG --> J["'Strain Differentiation (Wild-type vs. Vaccine')"]
I -- MS --> K["'Strain Differentiation (MS-H vs. Field')"]
I -- Negative --> L["Consider Culture or Sequencing"]
J --> M["Antimicrobial Susceptibility Testing"]
K --> M
M --> N["Integrated Control Strategy"]
F --> O["Test for Co-infections: AIV, NDV, Bacteria, Parasites"]
O --> E5. Control Strategies
5.1. Biosecurity and Management
The cornerstone of mycoplasma control is the establishment of mycoplasma-free breeding flocks through rigorous biosecurity measures [<a href="#ref-3">3</a>]. This includes the procurement of eggs and chicks from certified mycoplasma-free sources, strict all-in/all-out production systems, isolation of different age groups, and control of human and fomite movement [<a href="#ref-3">3</a>, <a href="#ref-44">44</a>]. Hatchery contamination is a critical risk factor, and stringent disinfection protocols are essential for preventing vertical transmission [<a href="#ref-11">11</a>]. Reducing stocking density, improving ventilation, and minimizing environmental stress are important for reducing the severity of clinical disease [<a href="#ref-3">3</a>, <a href="#ref-10">10</a>].
5.2. Vaccination
Vaccination is a widely used strategy to control mycoplasmosis in commercial layers and breeders [<a href="#ref-6">6</a>]. Both live-attenuated and inactivated vaccines are available for MG and MS [<a href="#ref-19">19</a>, <a href="#ref-20">20</a>]. Live vaccines, such as the F-strain and ts-11 strain for MG, and the MS-H strain for MS, confer partial protection by reducing clinical signs and transmission [<a href="#ref-20">20</a>, <a href="#ref-34">34</a>, <a href="#ref-45">45</a>, <a href="#ref-46">46</a>]. Recombinant vector vaccines, including those based on fowl poxvirus, fowl adenovirus, and Salmonella, are under development to provide safer and more efficacious alternatives [<a href="#ref-20">20</a>, <a href="#ref-47">47</a>, <a href="#ref-48">48</a>, <a href="#ref-49">49</a>]. Subunit and inactivated vaccines targeting specific immunogenic proteins, such as MSPA, P50, Pdhβ-PdhD, and LP53, have shown promise in experimental trials [<a href="#ref-25">25</a>, <a href="#ref-26">26</a>, <a href="#ref-50">50</a>, <a href="#ref-51">51</a>, <a href="#ref-52">52</a>, <a href="#ref-53">53</a>]. The combination of inactivated and subunit vaccines may enhance protective efficacy [<a href="#ref-51">51</a>]. Protective mechanisms of MS vaccines involve long-lasting plasma cell responses and antibody-mediated immunity [<a href="#ref-54">54</a>].
5.3. Antimicrobial Therapy and Resistance
Treatment of avian mycoplasmosis relies on antimicrobial agents that target protein synthesis, such as macrolides (e.g., tylosin, tilmicosin), tetracyclines (e.g., doxycycline, oxytetracycline), pleuromutilins (e.g., tiamulin, valnemulin), and fluoroquinolones (e.g., enrofloxacin) [<a href="#ref-5">5</a>, <a href="#ref-55">55</a>, <a href="#ref-56">56</a>]. However, the emergence and spread of antimicrobial resistance (AMR) in mycoplasmas is a growing concern [<a href="#ref-4">4</a>, <a href="#ref-5">5</a>, <a href="#ref-43">43</a>, <a href="#ref-57">57</a>]. Resistance to macrolides and fluoroquinolones has been reported in both MG and MS, often associated with mutations in target genes such as 23S rRNA and DNA gyrase [<a href="#ref-12">12</a>, <a href="#ref-57">57</a>, <a href="#ref-58">58</a>, <a href="#ref-59">59</a>]. Efflux pump mechanisms have also been identified in M. iowae [<a href="#ref-12">12</a>]. Pharmacokinetic/pharmacodynamic (PK/PD) modeling approaches are being used to optimize dosing regimens for novel pleuromutilin derivatives [<a href="#ref-55">55</a>, <a href="#ref-56">56</a>]. The routine application of antimicrobial susceptibility testing (AST) is recommended to guide therapy and mitigate further resistance development [<a href="#ref-4">4</a>, <a href="#ref-24">24</a>, <a href="#ref-59">59</a>, <a href="#ref-60">60</a>].
5.4. Alternative Control Approaches
Phytogenic compounds and herbal extracts are being investigated as alternatives to conventional antibiotics [<a href="#ref-14">14</a>, <a href="#ref-22">22</a>, <a href="#ref-61">61</a>, <a href="#ref-62">62</a>, <a href="#ref-63">63</a>]. Berberine has been shown to inhibit MS infection by suppressing inflammatory and apoptotic responses in avian macrophages [<a href="#ref-17">17</a>]. Luteolin and chrysosplenol D target the TatD nuclease of MG, disrupting its infectivity [<a href="#ref-14">14</a>, <a href="#ref-64">64</a>]. Scutellaria baicalensis extracellular vesicles attenuate MG-induced inflammation through inhibition of TRPC1-STIM1/ORAI1 calcium channels [<a href="#ref-62">62</a>]. Microemulsion formulations of essential oils have demonstrated synergistic effects against multi-resistant MG [<a href="#ref-65">65</a>]. Probiotics, such as Bacillus coagulans, have been investigated for their ability to improve resistance to MS infection when sprayed during incubation [<a href="#ref-66">66</a>].
5.5. Eradication and Surveillance
Eradication of MG and MS from breeder flocks is achievable through a combination of rigorous testing, culling of positive birds, and stringent biosecurity. National surveillance programs that involve molecular typing (e.g., MLST, vlhA genotyping) provide vital information on the genetic diversity and spread of field strains [<a href="#ref-31">31</a>, <a href="#ref-41">41</a>, <a href="#ref-42">42</a>, <a href="#ref-67">67</a>]. The prevalence of mycoplasmas in wild bird populations, including house finches and free-ranging turkeys, is a reservoir for potential spillback into domestic poultry [<a href="#ref-67">67</a>, <a href="#ref-68">68</a>, <a href="#ref-69">69</a>].
6. Conclusion
Avian mycoplasmosis remains a persistent challenge for the global poultry industry. The clinical signs, including greenish diarrhea, are not pathognomonic but serve as important indicators of systemic disease when combined with respiratory and joint pathology. The development of rapid, field-deployable molecular diagnostic assays has revolutionized the ability to detect and differentiate mycoplasma species, including vaccine and field strains [<a href="#ref-32">32</a>, <a href="#ref-36">36</a>, <a href="#ref-37">37</a>, <a href="#ref-38">38</a>, <a href="#ref-40">40</a>]. Effective control requires an integrated approach encompassing strict biosecurity, strategic vaccination, prudent antimicrobial use guided by susceptibility testing, and ongoing surveillance of pathogen emergence and antimicrobial resistance [<a href="#ref-3">3</a>, <a href="#ref-4">4</a>, <a href="#ref-6">6</a>]. The continued exploration of alternative therapeutic agents and novel vaccine platforms holds promise for more sustainable control strategies in the face of evolving antimicrobial resistance [<a href="#ref-22">22</a>, <a href="#ref-48">48</a>, <a href="#ref-52">52</a>, <a href="#ref-65">65</a>, <a href="#ref-66">66</a>].